| Welcome to FierceLifeSci Weekly Digest, your Friday roundup of the biggest and most popular stories from each of our publications.
Top Stories Of The Week Tuesday, June 21, 2016 They say there’s no such thing as a free lunch, and for doctors fed by drug companies, the old adage might be true. Even cheap meals provided by pharmaceutical sales reps were associated with higher prescription rates for the brands being promoted, a new JAMA Internal Medicine study concluded. Read more from FiercePharma Monday, June 20, 2016 Top pharma honors at the Cannes’ creative ad confab went to Philips for a heartwarming film for its medical devices. The short film, created by Ogilvy & Mather, follows the journey of 18 people with respiratory problems who learn from an expert coach how to sing again and put on a concert at Carnegie Hall. Read more from FiercePharmaMarketing Monday, June 20, 2016 Bayer, which is making moves to acquire agrochemical giant Monsanto, is said to be mulling a sale of its radiology supplies business potentially worth more than $3 billion, Reuters reported. Read more from FierceMedicalDevices Monday, June 20, 2016 The clinical trial landscape is witnessing an increase in Phase III trials that average more than 3,500 patients. As more of these large trials continue to emerge, many contract research organizations (CROs) and sponsors are struggling to recruit qualified clinical research associates (CRAs) to support the influx of work. Wednesday, June 22, 2016 India's drug regulator says 200 drugmakers in the country, including major local companies such as Mumbai-based Cipla and multinational Pfizer, are being inspected for producing poor-quality medicines. Read more from FiercePharmaAsia Friday, June 17, 2016 Takeda has signed up to work with M2Gen on the Oncology Research Information Exchange Network Avatar research program. The agreement, which comes two months after M2Gen unveiled ORIEN with Celgene as a founding member, gives Takeda access to deidentified clinical and molecular data generated at the 12 cancer care centers signed up to the program. Read more from FierceBiotechIT Tuesday, June 21, 2016 Scientists at the Oak Crest Institute of Science have shown in a first-of-its-kind result that an FDA-approved combination of the antiretroviral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) packed into an intravaginal ring could protect against HIV completely when delivered topically in animal tests. Read more from FierceDrugDelivery Monday, June 20, 2016 Sandoz, the generics and biosimilars unit of Novartis, has big ambitions when it comes to biosimilars. And the drugmaker is investing $1 billion in its manufacturing operations to realize them. Read more from FiercePharmaManufacturing Tuesday, June 21, 2016 Researchers from Washington University in St. Louis have identified a single gene that, if switched off, stops Zika and other flaviviruses from spreading in the body. Read more from FierceBiotechResearch Wednesday, June 22, 2016 Scotland’s trial tech company eClinicalHealth and partners Sanofi, U.K. consultant and ad company Langland and Finnish healthcare tech firm Mendor have posted positive results for their entirely remote online clinical study. Read more from FierceCRO Tuesday, June 21, 2016 Groups encouraging HPV vaccination will have more firepower for their arguments as a new analysis--citing a decade’s worth of real-world data for Merck’s Gardasil--documented dramatic HPV reductions following vaccine introduction in various countries. Read more from FierceVaccines Wednesday, June 15, 2016 Pet-drug developer Kindred Biosciences is launching a pilot field study to test molecules in dogs with atopic dermatitis, bolstering its commitment to R&D even after an early failure in the field. Read more from FierceAnimalHealth
Resources Sponsored by: Covance Al Blunt, MD, Executive Medical Director, Oncology at Covance discusses how the lessons learned from the past decade of developing targeted therapies are relevant to the future development of cancer immunotherapy. Download today!
|
